

Richard P. Kivel



Rich serves as CEO of TheraGenetics, Ltd. TheraGenetics is a London, England based company focused on the development and commercialization of pharmacogenetic diagnostic tests to help guide and improve the treatment of CNS disorders, such as Schizophrenia, Depression, ADHD and Alzheimer's. The technology, which was developed at King's College London, Institute of Psychiatry, is based upon genetic factors involved in influencing an individual's response to antipsychotic drugs. Rich joined the company as CEO in early 2006.

Rich is a frequent guest lecturer at the Massachusetts Institute of Technology (MIT) Sloan School of Management and has been a Judge for the MIT \$50K / \$100K Entrepreneurship Competition since 1998. Rich also serves on the Global Board of Directors of the MIT Enterprise Forum and serves as a Lead Catalyst for the MIT Deshpande Center for Technological Innovation and is a founding board member of Biolink USA-Ireland.

Rich earned an M.S. in Management from Boston College, a B.A. from American International College and has completed the "Advanced Course in Genomics, Drug Discovery, Therapeutics and New Innovations" at the University of Pennsylvania. He is also a graduate of the prestigious MIT Executive Management Program, "Birthing of Giants".

Rich has been selected for the "All Star" award for Biotechnology by Mass High Tech: Journal of New England Technology and by the Boston Business Journal as one of its "40-under-40"; top forty most promising business people under 40 in Massachusetts.

Rich lives in Boston, MA and London, England and can be reached at rich@kivel.net or +1-617-697-0952